You may qualify and be compensated up to $2,000 if you meet the following requirements:
Study design: a screening visit and 2 in-patient stays of 2 nights and 3 days separated by 4 days of washout between each stay.
Study objective: The trial’s main objective is to evaluate the pharmacodynamic response to RNS60 by measuring brain activity in healthy participants using EEG. In addition, blood will be collected for biomarker analysis.
For more information, contact our recruiters at 844-246-8459 or email us at recruitment@biotrial.us
Click here for the study calendars.
About the study drug: The study drug, RNS60, is an electrokinetically altered aqueous fluid composed of saline and oxygen, which does not contain a chemical active pharmaceutical ingredient. Therefore, its biological effects have been attributed to its physical properties.
RNS60 has been tested via intravenous and inhalation routes of administration. It has been well tolerated in all clinical studies, including in healthy participants and patients with mild to moderate asthma, people with amyotrophic lateral sclerosis (ALS), patients with multiple sclerosis, and patients with acute ischemic stroke.
Share this study:
Complete the registration form and call us at 844-246-8459. Our recruiters will be happy to help you, and it will take 5 minutes of your time to know if you are eligible. Your information will be kept strictly confidential.